Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Mar;5(3):167-72.
doi: 10.1038/ncpendmet1067.

Generalized arterial calcification of infancy: treatment with bisphosphonates

Affiliations
Case Reports

Generalized arterial calcification of infancy: treatment with bisphosphonates

Kim A Ramjan et al. Nat Clin Pract Endocrinol Metab. 2009 Mar.

Abstract

Background: A baby girl developed respiratory distress immediately after birth and required supplemental oxygen. She was born at term via lower-segment cesarean section. The parents were nonconsanguineous, and antenatal ultrasonography during the pregnancy at 18 and 32 weeks of gestation did not reveal any abnormalities. On examination at birth, no pulses were palpable; however, the baby's blood pressure was normal and no remarkable abnormalities were detected. Ultrasonography revealed widespread arterial calcification.

Investigations: Chest and abdominal radiography at birth and serial abdominal, renal and cardiac ultrasonography at follow-up examinations; dual-energy X-ray absorptiometry during treatment with bisphosphonates; genetic screening.

Diagnosis: Generalized arterial calcification of infancy, secondary to compound, heterozygous mutations in the ENPP1 gene, pL661V and pE668K of the paternal chromosome, and pN792S in the maternal chromosome.

Management: Low-dose disodium pamidronate (0.1 mg/kg per week for 4 weeks), which commenced on the seventh day after birth and was changed to oral risedronate sodium (1 mg/kg per week as a single dose) at 4 weeks of age. Complete resolution of arterial calcification was seen by 3 months of age. At 12 months, ergocalciferol was added at a dose of 5,000 U daily for 6 weeks, followed by 200 U daily owing to the patient's vitamin D deficiency and elevated parathyroid hormone level. Treatment with bisphosphonates is ongoing, but is planned to be discontinued at 3 years of age. The child has remained healthy and developmentally normal.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Pediatr Radiol. 2006 Mar;36(3):247-53 - PubMed
    1. Eur J Pediatr. 2006 Apr;165(4):258-63 - PubMed
    1. Eur J Pediatr. 2006 Sep;165(9):590-3 - PubMed
    1. J Pediatr. 1978 Mar;92(3):401-5 - PubMed
    1. Eur J Pediatr. 1989 Jan;148(4):374-7 - PubMed

Publication types

LinkOut - more resources